PepGen Ltd Market Cap ($169.46 Million)
Market Cap & Net Worth: PepGen Ltd (PEPG)
PepGen Ltd market cap. PepGen Ltd (NASDAQ:PEPG) has a market capitalization of $169.46 Million ($169.46 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #17019 globally and #4053 in its home market, demonstrating a -5.77% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PepGen Ltd's stock price $2.45 by its total outstanding shares 69169215 (69.17 Million). Also see PEPG operating cash flow for how efficiently the company converts equity into cash flow.
PepGen Ltd Market Cap History (2022–2026)
PepGen Ltd market cap history from 2022 to 2026. Data shows change from $924.79 Million to $169.46 Million (-30.85% CAGR). Check PepGen Ltd (PEPG) stock price for real-time trading data and today's change.
Index Memberships
PepGen Ltd is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.01% | #461 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.00% | #1665 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.01% | #226 of 263 |
Weight: PepGen Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
PepGen Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PepGen Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore PEPG year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PEPG by Market Capitalization
Companies near PepGen Ltd in the global market cap rankings as of November 5, 2026. Also see PepGen Ltd total assets for a full breakdown of the balance sheet.
Key companies related to PepGen Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of PepGen Ltd (2022–2026)
Market capitalization of PepGen Ltd from 2022 to today. Between 2022 and today, PepGen Ltd's market cap moved from $924.79 Million to $ 169.46 Million, with a yearly change of -30.85%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $169.46 Million | -62.37% |
| 2025 | $450.29 Million | +71.77% |
| 2024 | $262.15 Million | -44.26% |
| 2023 | $470.35 Million | -49.14% |
| 2022 | $924.79 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of PepGen Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $169.46 Million USD |
| MoneyControl | $169.46 Million USD |
| MarketWatch | $169.46 Million USD |
| marketcap.company | $169.46 Million USD |
| Reuters | $169.46 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About PepGen Ltd
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatm… Read more